Last updated: 20 June 2024 at 6:09pm EST

Kenneth Hoberman Net Worth




The estimated Net Worth of Kenneth Hoberman is at least $22.7 Milhão dollars as of 9 March 2020. Mr. Hoberman owns over 26,191 units of TG Therapeutics Inc stock worth over $17,804,595 and over the last 11 years he sold TGTX stock worth over $4,606,522. In addition, he makes $245,000 as Independent Director at TG Therapeutics Inc.

Mr. Hoberman TGTX stock SEC Form 4 insiders trading

Kenneth has made over 31 trades of the TG Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 26,191 units of TGTX stock worth $130,169 on 9 March 2020.

The largest trade he's ever made was exercising 112,940 units of TG Therapeutics Inc stock on 22 November 2013 worth over $125,363. On average, Kenneth trades about 10,697 units every 44 days since 2013. As of 9 March 2020 he still owns at least 771,764 units of TG Therapeutics Inc stock.

You can see the complete history of Mr. Hoberman stock trades at the bottom of the page.





Kenneth Hoberman biography

Kenneth Hoberman serves as Independent Director of the Company. Mr. Hoberman is currently the Chief Operating Officer and Corporate Secretary of Stemline Therapeutics, Inc. where he was a key member of the founding team. He was instrumental in the company’s financings from early private, including institutional, rounds through the IPO and subsequent follow-on offerings. He has extensive financial, accounting, investor relations, corporate governance and business development experience including M&A, strategic alliances and partnerships both domestic and international. His operational expertise includes regulatory oversight, human resources, manufacturing and clinical development. He was previously Vice President of Corporate and Business Development of Keryx Biopharmaceuticals, Inc., where he was instrumental in the success of the company. He also helped secure multiple sources of capital including over $200 million in equity investments through public and private offerings. He also initiated and executed a $100 million strategic alliance and originated, negotiated and closed dozens of licensing and operational contracts, helping to grow the company’s market capitalization to over $1 billion. He also led the team that originated, in-licensed, and developed AuryxiaTM which recently gained FDA approval. He received a B.S.B.A. in Finance from Boston University and completed post-baccalaureate studies at Columbia University. Based on Mr. Hoberman’s financial and pharmaceutical industry experience and in-depth understanding of our business, as well as his extensive management experience, the Board of Directors believes that Mr. Hoberman has the appropriate set of skills to serve as a member of the Board.

What is the salary of Kenneth Hoberman?

As the Independent Director of TG Therapeutics Inc, the total compensation of Kenneth Hoberman at TG Therapeutics Inc is $245,000. There are 5 executives at TG Therapeutics Inc getting paid more, with Michael Weiss having the highest compensation of $12,674,700.



How old is Kenneth Hoberman?

Kenneth Hoberman is 55, he's been the Independent Director of TG Therapeutics Inc since 2014. There are 3 older and 5 younger executives at TG Therapeutics Inc. The oldest executive at TG Therapeutics Inc is William Kennedy, 75, who is the Independent Director.

What's Kenneth Hoberman's mailing address?

Kenneth's mailing address filed with the SEC is 3020 CARRINGTON MILL BLVD, SUITE 475, , MORRISVILLE, NC, 27560.

Insiders trading at TG Therapeutics Inc

Over the last 12 years, insiders at TG Therapeutics Inc have traded over $23,556,837 worth of TG Therapeutics Inc stock and bought 549,710 units worth $3,334,566 . The most active insiders traders include Capital Management, L.P.Kol..., Michael S Weiss, eSean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of $1,103,023. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth $432,822.



What does TG Therapeutics Inc do?

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".



What does TG Therapeutics Inc's logo look like?

TG Therapeutics Inc logo

Complete history of Mr. Hoberman stock trades at Stemline Therapeutics e TG Therapeutics Inc

Data
#
Companhia
Acionista maioritário
Trans.
Transação
Ações Preço por ação Preço total Ações após Fonte
9 Mar 2020 Kenneth Hoberman
Diretor de Operações
Venda 26,191 $4.97 $130,169
9 Mar 2020
771,764
25 Feb 2020 Kenneth Hoberman
Diretor de Operações
Venda 11,547 $6.42 $74,132
25 Feb 2020
797,955
22 Jan 2020 Kenneth Hoberman
Diretor de Operações
Venda 22,139 $7.02 $155,416
22 Jan 2020
601,085
8 Jan 2020 Kenneth Hoberman
Diretor de Operações
Venda 13,228 $10.37 $137,174
8 Jan 2020
623,224
23 Dec 2019 Kenneth Hoberman
Diretor de Operações
Venda 46,312 $10.84 $502,022
23 Dec 2019
636,452
24 Jun 2019 Kenneth Hoberman
Diretor de Operações
Venda 47,115 $15.07 $710,023
24 Jun 2019
682,764
13 May 2019 Kenneth Hoberman
Diretor de Operações
Venda 25,817 $14.27 $368,409
13 May 2019
729,879
11 Mar 2019 Kenneth Hoberman
Diretor de Operações
Venda 26,082 $11.11 $289,771
11 Mar 2019
755,696
7 Mar 2019 Kenneth Hoberman
Diretor de Operações
Venda 2,995 $11.36 $34,023
7 Mar 2019
781,778
25 Feb 2019 Kenneth Hoberman
Diretor de Operações
Venda 10,557 $12.05 $127,212
25 Feb 2019
784,773
8 Jan 2019 Kenneth Hoberman
Diretor de Operações
Venda 13,547 $10.15 $137,502
8 Jan 2019
646,652
26 Nov 2018 Kenneth Hoberman
Diretor de Operações
Venda 26,296 $11.85 $311,608
26 Nov 2018
659,738
12 Mar 2018 Kenneth Hoberman
Diretor de Operações
Venda 29,987 $17.14 $513,977
12 Mar 2018
409,594
7 Mar 2018 Kenneth Hoberman
Diretor de Operações
Venda 3,027 $16.55 $50,097
7 Mar 2018
369,278
26 Feb 2018 Kenneth Hoberman
Diretor de Operações
Venda 11,026 $17.43 $192,183
26 Feb 2018
371,915
15 Feb 2018 Kenneth Hoberman
Diretor de Operações
Venda 1,851 $15.67 $29,005
15 Feb 2018
382,941
8 Jan 2018 Kenneth Hoberman
Diretor de Operações
Venda 14,040 $13.93 $195,577
8 Jan 2018
384,792
15 Dec 2017 Kenneth Hoberman
Diretor de Operações
Venda 11,983 $14.18 $169,919
15 Dec 2017
398,832
7 Mar 2017 Kenneth Hoberman
Diretor de Operações
Venda 2,342 $8.16 $19,111
7 Mar 2017
277,674
27 Feb 2017 Kenneth Hoberman
Diretor de Operações
Venda 8,027 $6.99 $56,109
27 Feb 2017
279,655
16 Feb 2017 Kenneth Hoberman
Diretor de Operações
Venda 1,508 $6.42 $9,681
16 Feb 2017
287,682
10 Jan 2017 Kenneth Hoberman
Diretor de Operações
Venda 9,110 $13.82 $125,900
10 Jan 2017
289,190
8 Mar 2016 Kenneth Hoberman
Diretor de Operações
Venda 2,412 $5.34 $12,880
8 Mar 2016
297,392
17 Feb 2016 Kenneth Hoberman
Diretor de Operações
Venda 1,503 $4.54 $6,824
17 Feb 2016
211,059
19 Mar 2015 Kenneth Hoberman
Diretor de Operações
Exercício de opção 27,105 $4.09 $110,859
19 Mar 2015
139,426
19 Mar 2015 Kenneth Hoberman
Diretor de Operações
Exercício de opção 27,105 $4.09 $110,859
19 Mar 2015
139,426
18 Feb 2015 Kenneth Hoberman
Diretor de Operações
Venda 1,593 $14.02 $22,334
18 Feb 2015
87,942
18 Feb 2015 Kenneth Hoberman
Diretor de Operações
Venda 1,593 $14.02 $22,334
18 Feb 2015
87,942
2 Sep 2014 Kenneth Hoberman
Diretor de Operações
Comprar 2,000 $10.99 $21,980
2 Sep 2014
89,535
21 May 2014 Kenneth Hoberman
Diretor de Operações
Venda 15,250 $13.32 $203,130
21 May 2014
87,535
22 Nov 2013 Kenneth Hoberman
Diretor de Operações
Exercício de opção 112,940 $1.11 $125,363
22 Nov 2013
103,211


TG Therapeutics Inc executives and stock owners

TG Therapeutics Inc executives and other stock owners filed with the SEC include: